



## Half-year report on the liquidity contract between Safe Orthopaedics and Louis Capital Markets

Eragny-sur-Oise, France, January 12th, 2021 - 18h00 CEST – Safe Orthopaedics (FR0013467123 - ALSAF), a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated, is today releasing its half-year report on the liquidity contract signed with Louis Capital Markets.

Under the contract, the liquidity account had the following holdings as of December 31<sup>st</sup>, 2020:

- 584 shares
- -35,87 euros

During the first half of 2020, the following have been negotiated:

PURCHASE	4,582 shares	1,803.84 euros	513 transactions
SALE	5,010 shares	1,947.17 euros	503 transactions

For the prior period (June 30<sup>th</sup>, 2020), the corresponding figures were:

- 1 012 shares
- 364,57 euros

As of March 18, 2019 (implementation of the new liquidity contract), the followings were made available:

- 74 738 shares
- 7 561,33 euros

Following the acquisition of Louis Capital Market|Midcap Partners by the group TPICAP Plc, the liquidity contract previously owned by Louis Capital Markets UK, LLP has been automatically transferred on 31/12/2020 to TP ICAP (EUROPE), the French entity of the group TPICAP, authorized and regulated by the French *Autorité de Contrôle Prudentiel et de Résolution* (ACPR) and the *Autorité des Marchés Financiers* (AMF).



The detail of day-to-day activities is as follows:

ALSAF FP	Purchase			Sale		
	Trading volume	Number of shares	Cash (EUR)	Trading volume	Number of shares	Cash (EUR)
Total	513	4 582	1 803,84	503	5 010	1 947,17
20200701	4	59	29,32	1	1	0,50
20200702	3	38	18,60	6	101	51,73
20200703	5	75	36,77	5	60	31,07
20200706	1	1	0,52	9	158	82,22
20200707	4	71	35,64	5	62	32,71
20200708	4	57	28,40	2	21	10,75
20200709	4	56	27,30	1	1	0,49
20200710	5	65	30,90	1	1	0,48
20200713	2	14	6,45	5	71	33,60
20200714	3	35	16,15	4	56	26,75
20200715	4	55	25,63	1	1	0,48
20200716	2	15	6,90	4	56	26,41
20200717	1	1	0,48	5	67	32,33
20200720	5	75	35,28	2	12	5,82
20200721	3	38	18,30	1	1	0,49
20200722	1	1	0,49	6	119	59,14
20200723	5	58	28,61	2	21	10,67
20200724	4	32	15,39	1	1	0,49
20200727	3	22	10,49	11	202	105,98
20200728	4	51	24,87	5	57	28,71
20200729	4	51	24,84	2	2	1,00
20200730	4	46	22,17	4	50	24,93
20200731	4	39	18,42	1	1	0,47
20200803	3	24	11,50	2	21	10,29
20200804	4	18	8,48	4	56	27,10
20200805	5	22	10,26	2	21	10,11
20200806	2	4	1,88	2	221	103,02
20200807	4	25	11,59	2	19	9,01
20200810	5	21	9,67	3	30	14,25
20200811	1	1	0,69	11	145	100,76
20200812	8	57	28,86	2	15	7,95
20200813	7	48	22,87	1	1	0,49
20200814	5	32	14,45	6	78	36,63
20200817	5	37	17,21	2	16	7,65
20200818	4	24	10,95	3	21	9,87
20200819	4	24	10,78	2	9	4,14
20200820	6	41	17,55	1	1	0,45
20200821	4	22	9,22	1	1	0,43
20200824	1	1	0,43	4	44	18,81
20200825	2	5	2,07	2	14	5,88



20200826	3	19	7,84	3	22	9,30
20200827	4	24	9,88	3	22	9,35
20200828	2	10	4,09	4	41	17,23
20200831	4	27	11,03	2	9	3,76
20200901	6	46	17,69	1	1	0,39
20200902	4	23	8,62	1	1	0,38
20200903	1	1	0,38	4	44	16,77
20200904	1	1	0,38	3	22	8,35
20200907	5	38	13,90	5	56	21,47
20200908	3	23	8,61	6	67	26,80
20200909	5	45	16,75	4	36	14,04
20200910	3	26	9,47	6	60	22,71
20200911	4	35	13,11	1	1	0,38
20200914	4	32	11,85	4	36	13,86
20200915	4	32	11,84	1	1	0,37
20200916	1	1	0,37	4	39	14,56
20200917	3	27	10,04	1	1	0,37
20200918	3	21	7,78	1	1	0,38
20200921	4	30	10,94	4	40	15,20
20200922	3	25	8,88	4	39	14,39
20200923	4	32	11,52	3	20	7,39
20200924	4	32	11,37	4	39	14,31
20200925	4	34	11,90	2	8	2,87
20200928	2	9	3,18	6	72	26,55
20200929	4	36	12,65	5	48	18,14
20200930	3	25	8,97	2	10	3,69
20201001	1	1	0,35	2	10	3,55
20201002	6	63	21,69	1	1	0,35
20201005	5	50	16,52	11	125	45,09
20201006	10	92	37,69	5	50	22,08
20201007	3	25	9,55	6	71	28,12
20201008	5	52	20,68	1	1	0,40
20201009	11	100	35,72	1	1	0,36
20201012	7	53	18,56	1	1	0,36
20201013	1	1	0,35	3	31	10,80
20201014	1	1	0,34	1	1	0,34
20201015	4	29	9,77	1	1	0,34
20201016	2	10	3,36	1	1	0,34
20201019	2	10	3,34	3	32	10,89
20201020	6	42	13,84	1	1	0,33
20201021	5	33	10,38	4	53	17,23
20201022	5	37	11,35	1	1	0,32
20201023	7	45	13,31	2	4	1,23
20201026	11	62	17,45	4	54	16,54
20201027	9	49	12,47	2	21	5,66
20201028	10	58	13,41	1	1	0,24
20201029	7	35	7,37	2	21	4,60



20201030	5	25	5,13	10	161	35,23
20201102	1	1	0,23	9	134	30,66
20201103	2	15	3,47	7	90	21,59
20201104	4	47	11,26	5	53	13,10
20201105	10	119	27,56	4	41	10,20
20201106	1	1	0,25	11	135	33,90
20201109	5	66	16,25	4	33	8,59
20201110	5	62	15,00	2	12	3,00
20201111	3	29	6,97	2	15	3,69
20201112	2	19	4,57	4	39	9,64
20201113	2	20	4,83	2	15	3,69
20201116	1	1	0,25	9	94	24,39
20201117	3	32	8,28	5	37	10,01
20201118	6	77	19,84	2	11	2,96
20201119	3	30	7,55	1	1	0,25
20201120	4	43	10,59	4	38	9,75
20201123	1	1	0,26	4	39	10,14
20201124	2	20	5,03	3	30	7,74
20201125	3	32	7,97	3	30	7,72
20201126	3	27	6,72	4	41	10,57
20201127	1	1	0,25	4	33	8,39
20201130	2	21	5,29	2	13	3,34
20201201	1	1	0,26	11	101	27,90
20201202	1	1	0,29	4	25	7,13
20201203	4	53	14,42	5	29	8,67
20201204	3	34	9,24	2	10	2,80
20201207	4	51	13,61	4	27	7,54
20201208	4	55	14,82	4	31	8,62
20201209	5	66	17,37	1	1	0,27
20201210	5	65	16,94	3	24	6,46
20201211	1	1	0,27	1	1	0,27
20201214	1	1	0,27	7	81	21,61
20201215	4	52	13,61	11	103	28,68
20201216	4	58	15,18	9	77	21,66
20201217	1	1	0,28	11	85	24,37
20201218	5	81	22,10	6	40	11,43
20201221	4	58	15,33	11	77	21,63
20201222	1	1	0,35	11	63	22,21
20201223	1	1	0,90	11	44	39,60
20201224	11	74	75,07	6	11	12,20
20201225	0	0	0,00	0	0	0,00
20201228	0	0	0,00	0	0	0,00
20201229	10	136	89,82	0	0	0,00
20201230	9	119	63,52	11	31	18,72
20201231	10	121	81,71	1	1	0,69



**Next financial release:**

Annual 2020 results, January 14<sup>th</sup>, 2021 (post-market)

**About Safe Orthopaedics**

Founded in 2010, Safe Orthopaedics is a French medical technology company, a pioneer of the design and marketing of innovative ready-to-use technologies (single-use implants and instruments) for spinal fractures treatments. The company develops and manufactures kits combining sterile implants and single-use instruments, available at any time for the surgeon. These technologies enable minimally invasive approach, reducing the risk of cross contamination and infection, in the interest of the patient with a positive impact on hospitalization durations and costs. Protected by 17 patent families, the SteriSpine<sup>TM</sup> PS are CE marked and FDA approved. Safe Orthopaedics has its headquarters close to Paris (95610 Eragny-sur-Oise - France) has subsidiaries in the UK, Germany, United States and in the Lyon area where the manufacturing company is located. The Group employs around 150 employees.

For more information : [www.SafeOrthopaedics.com](http://www.SafeOrthopaedics.com)

**Contacts**

**Safe Orthopaedics**

François-Henri Reynaud  
*Chief Financial Officer*  
Tél. : +33 (0)1 34 21 50 00  
[investors@safeorthopaedics.com](mailto:investors@safeorthopaedics.com)



**Press Relations**

**Ulysse Communication**

Pierre-Louis Germain / +33 (0)6 64 79 97 61 / [plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)  
Bruno Arabian / +33 (0)6 87 88 47 26 / [barabian@ulyse-communication.com](mailto:barabian@ulyse-communication.com)